The invention is directed to a class of compounds, including the pharmaceutically acceptable salts of the compounds, having the structure of formula I:

##STR00001##

as defined in the specification. The invention is also directed to compositions containing and uses of the compounds of formula I.

The invention is directed to a class of compounds, including the pharmaceutically acceptable salts of the compounds, having the structure of formula I:

##STR00001##

as defined in the specification. The invention is also directed to compositions containing and uses of the compounds of formula I.

Compounds of formula (VII), which are useful as inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan dioxygenase, are provided. Also provided are pharmaceutical compositions, kits comprising said compounds, and methods and uses pertaining to said compounds.

Compounds of formula (VII), which are useful as inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan dioxygenase, are provided. Also provided are pharmaceutical compositions, kits comprising said compounds, and methods and uses pertaining to said compounds.

The present disclosure provides, for example, a compound represented by the general formula below or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate of the compound or salt: ##STR00001##
wherein X.sub.1, X.sub.2, X.sub.3 and X.sub.4 are each independently CR.sub.2? or N?, R.sub.2 is, for example, a halogen atom, R.sub.1 is, for example, S(?O).sub.2NHR.sub.8, R.sub.8 is, for example, a C.sub.1-6 alkyl group, R.sub.3 is, for example, a hydrogen atom, R.sub.5 is, for example, a halogen atom, R.sub.6 is, for example, a hydrogen atom, and R.sub.4 is, for example, a cyclopropyl group. The compounds, salts or solvates provided by the present disclosure exhibit high RAF/MEK complex-stabilizing activity and can be used for the treatment or prevention of cell proliferative disorders, particularly cancers.

The present disclosure provides, for example, a compound represented by the general formula below or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate of the compound or salt: ##STR00001##
wherein X.sub.1, X.sub.2, X.sub.3 and X.sub.4 are each independently CR.sub.2? or N?, R.sub.2 is, for example, a halogen atom, R.sub.1 is, for example, S(?O).sub.2NHR.sub.8, R.sub.8 is, for example, a C.sub.1-6 alkyl group, R.sub.3 is, for example, a hydrogen atom, R.sub.5 is, for example, a halogen atom, R.sub.6 is, for example, a hydrogen atom, and R.sub.4 is, for example, a cyclopropyl group. The compounds, salts or solvates provided by the present disclosure exhibit high RAF/MEK complex-stabilizing activity and can be used for the treatment or prevention of cell proliferative disorders, particularly cancers.

Provided herein are solid forms comprising (a) 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione and (b) a coformer. Pharmaceutical compositions comprising the solid forms (e.g., cocrystals) and methods for treating, preventing and managing various disorders are also disclosed.

Provided herein are solid forms comprising (a) 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione and (b) a coformer. Pharmaceutical compositions comprising the solid forms (e.g., cocrystals) and methods for treating, preventing and managing various disorders are also disclosed.

Dimethylamine (Me.sub.2NH) is reacted with sulfuryl fluoride (SO.sub.2F.sub.2) to form at least a first phase comprising N-(fluorosulfonyl) dimethylamine (FSO.sub.2NMe.sub.2), tetramethylsulfamide (SO.sub.2(NMe.sub.2).sub.2), or a combination thereof. A second phase, which may include dimethylamine hydrofluoride (Me.sub.2NH.sub.2F), may be also formed and separated from the first phase. FSO.sub.2NMe.sub.2 or SO.sub.2(NMe.sub.2).sub.2 is then isolated from the first phase. For example, the first phase may be a liquid phase, and FSO.sub.2NMe.sub.2 and SO.sub.2(NMe.sub.2).sub.2 are separated by distillation, optionally under reduced pressure.

Dimethylamine (Me.sub.2NH) is reacted with sulfuryl fluoride (SO.sub.2F.sub.2) to form at least a first phase comprising N-(fluorosulfonyl) dimethylamine (FSO.sub.2NMe.sub.2), tetramethylsulfamide (SO.sub.2(NMe.sub.2).sub.2), or a combination thereof. A second phase, which may include dimethylamine hydrofluoride (Me.sub.2NH.sub.2F), may be also formed and separated from the first phase. FSO.sub.2NMe.sub.2 or SO.sub.2(NMe.sub.2).sub.2 is then isolated from the first phase. For example, the first phase may be a liquid phase, and FSO.sub.2NMe.sub.2 and SO.sub.2(NMe.sub.2).sub.2 are separated by distillation, optionally under reduced pressure.